| Literature DB >> 33288784 |
Zeid Mahmood1, Anette Davidsson1, Eva Olsson1, Per Leanderson2, Anna K Lundberg3, Lena Jonasson4.
Abstract
Vulnerability to stress-induced inflammation has been linked to a dysfunctional hypothalamus-pituitary-adrenal (HPA) axis. In the present study, patients with known or suspected coronary artery disease (CAD) were assessed with respect to inflammatory and HPA axis response to acute physical exercise. An exercise stress test was combined with SPECT myocardial perfusion imaging. Plasma and saliva samples were collected before and 30 min after exercise. Interleukin (IL)-6 and adrenocorticotropic hormone (ACTH) were measured in plasma, while cortisol was measured in both plasma and saliva. In total, 124 patients were included of whom 29% had a prior history of CAD and/or a myocardial perfusion deficit. The levels of exercise intensity and duration were comparable in CAD and non-CAD patients. However, in CAD patients, IL-6 increased after exercise (p = 0.019) while no differences were seen in HPA axis variables. Conversely, patients without CAD exhibited increased levels of ACTH (p = 0.003) and cortisol (p = 0.004 in plasma, p = 0.006 in saliva), but no change in IL-6. We conclude that the IL-6 response to acute physical exercise is exaggerated in CAD patients and may be out of balance due to HPA axis hypoactivity. It remains to be further investigated whether this imbalance is a potential diagnostic and therapeutic target in CAD.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33288784 PMCID: PMC7721799 DOI: 10.1038/s41598-020-78286-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The role of the hypothalamic–pituitary–adrenal (HPA) axis as a regulator of stress response and inflammation. LEFT: Normally, the stress-induced release of cytokines, like IL-6, activates the HPA axis resulting in rapid increases of adrenocorticotropic hormone (ACTH) and cortisol. Cortisol will, as a feedback, suppress further release of cytokines. RIGHT: Hypothetically, a blunted HPA axis response leads to inadequate downregulation of stress-induced inflammatory cytokines.
Demographic and clinical characteristics, including medication and laboratory variables, of all patients and patients divided into two subgroups: those with documented CAD, defined as a history of prior MI and/or coronary revascularization and/or a myocardial perfusion deficit, and those with no signs of CAD, i.e. no history of prior CAD events and normal SPECT MPI (non-CAD).
| All patients | CAD | Non-CAD | pa | |
|---|---|---|---|---|
| Age, years | 67 (57–73) | 67 (59–73) | 66 (56–73) | NS |
| Female, n (%) | 49 (40) | 6 (17) | 43 (49) | 0.001 |
| BMI | 27 (24–30) | 27 (25–30) | 27 (24–29) | NS |
| Smokers, n (%) | 15 (12) | 7 (19) | 8 (9.1) | NS |
| Hypertension, n (%) | 65 (52) | 20 (56) | 45 (51) | NS |
| Diabetes, n (%) | 20 (16) | 8 (22) | 12 (14) | NS |
| Statin, n (%) | 61 (49) | 28 (78) | 33 (38) | < 0.001 |
| Beta blockers, n (%) | 50 (40) | 23 (64) | 27 (31) | 0.002 |
| ACEI/ARB, n (%) | 63 (51) | 25 (69) | 38 (43) | 0.029 |
| Calcium channel blockers, n (%) | 20 (16) | 4 (11) | 16 (18) | NS |
| Low dose aspirin, n (%) | 54 (44) | 28 (78) | 26 (30) | < 0.000 |
| Creatinine, μmol/L | 82 (69–96) | 85 (70–97) | 81 (68–95) | NS |
| CRP, mg/L | 1.0 (0.5–2.6) | 0.9 (0.5–1.5) | 1.2 (0.5–2.6) | NS |
aCAD vs non-CAD. BMI, body mass index; ACEI/ARB, angiotensin converting enzyme inhibitors/angiotensin receptor blockers; CRP, C-reactive protein.
Results from exercise stress test and myocardial perfusion imaging of all patients and patients divided into two subgroups: those with documented CAD, defined as a history of prior MI and/or coronary revascularization and/or a myocardial perfusion deficit, and those with no signs of CAD, i.e. no history of prior CAD events and normal SPECT MPI (non-CAD).
| All patients | CAD | Non-CAD | pa | ||
|---|---|---|---|---|---|
| Heart rate, beats/min | Baseline | 70 (63–80) | 68 (63–78) | 71 (63–80) | NS |
| Maximum | 142 (133–155) | 138 (133–153 | 142 (131–155) | NS | |
| Systolic blood pressure, mm Hg | Baseline | 138 (125–150) | 140 (120–150) | 135 (125–150) | NS |
| Maximum | 190 (180–210) | 193 (180–210) | 190 (180–210) | NS | |
| Diastolic blood pressure, mm Hg | Baseline | 80 (70–88) | 80 (70–85) | 80 (70–90) | NS |
| Maximal workload, watts | 127 (100–178) | 121 (95–184) | 130 (102–174) | NS | |
| Exercise duration, min | 7.3 (6.2–8.3) | 7.3 (6.4–8.6) | 7.3 (6.1–8.2) | NS | |
| Left ventricular ejection fraction < 50%, n (%) | 10 (8.2) | 7 (19) | 3 (3.5) | 0.007 | |
| Exercise-induced chest pain, n (%) | 17 (14) | 6 (17) | 11 (13) | NS | |
| Myocardial perfusion deficit, n (%) | 19 (15) | 19 (53) | – | ||
| Reversible myocardial perfusion deficitb, n (%) | 15 (12) | 15 (42) | – | ||
aCAD vs non-CAD.
bTotal perfusion deficit, TPD, ≥ 5%.
Biochemical measures before and after exercise in all patients and patients divided into two subgroups: those with documented CAD, defined as a history of prior MI and/or coronary revascularization and/or a myocardial perfusion deficit, and those with no signs of CAD, i.e. no history of prior CAD events and normal SPECT MPI (non-CAD).
| All patients | CAD | Non-CAD | pa | |
|---|---|---|---|---|
| Baseline | 2.81 (2.17–4.03) | 2.90 (2.40–4.01) | 2.81 (2.02–4.36) | NS |
| Exercise | 3.11 (2.27–4.33) | 3.18 (2.55–4.13) | 2.85 (2.07–4.40) | NS |
| pa | 0.035 | 0.019 | NS | |
| Baseline | 3.13 (2.13–4.33) | 3.43 (2.43–5.08) | 3.06 (1.96–4.25) | NS |
| Exercise | 3.57 (2.29–5.30) | 3.34 (2.01–6.28) | 3.59 (2.30–5.18) | NS |
| pa | 0.001 | NS | 0.003 | |
| Baseline | 326 (266–401) | 344 (264–415) | 319 (264–398) | NS |
| Exercise | 354 (286–443) | 339 (286–474) | 356 (278–435) | NS |
| pa | < 0.001 | NS | 0.004 | |
| Baseline | 6.3 (4.0–9.3) | 8.2 (3.0–11.3) | 6.0 (4.3–8.6) | NS |
| Exercise | 8.2 (6.0–14.8) | 7.5 (5.9–20.7) | 8.2 (5.9–13.9) | NS |
| pa | 0.001 | NS | 0.006 | |
| Baseline | 11.3 (7.8–15.9) | 10.3 (6.3–15.9) | 11.3 (8.1–16.1) | NS |
| Exercise | 12.9 (8.7–17.8) | 11.0 (6.9–18.1) | 13.2 (9.1–17.3) | NS |
| pa | < 0.001 | 0.019 | < 0.001 | |
aCAD vs non-CAD. Baseline vs exercise. IL-6, interleukin-6; ACTH, adrenocorticotrophic hormone; FABP4, fatty acid binding protein-4.
Figure 2The proportions (%) of IL-6 high responders among patients with documented CAD, defined as a history of prior MI and/or coronary revascularization and/or a myocardial perfusion deficit (n = 36), in patients with a history of prior MI (n = 25) and in patients with no signs of CAD, i.e. no history of prior CAD events and normal SPECT MPI (n = 88).